The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2023 | Key highlights in MPNs at ASH 2023: novel agents & combinations, ongoing clinical trials, and more
In this discussion, Ruben Mesa, MD, Levine Cancer Institute, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston Salem, NC, Claire Harrison, MD, FRCP, FRCPath, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, and Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, share their key highlights in myeloproliferative neoplasms (MPNs) from this year’s ASH Annual Meeting. The experts cover a variety of topics, including novel agents being explored in essential thrombocythemia (ET) and developments being made in the field of polycythemia vera (PV). Other topics addressed include the importance of improving strategies to monitor disease progression in patients with MPNs, and novel JAK inhibitor combinations being explored in myelofibrosis (MF). This discussion took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
